ModernAminos

MOTS-C restored intracellular peptide levels and activated AMPK signaling in obese-donor mesenchymal stromal cells in a 2026 Mayo Clinic study. Reaching the target pathway did not translate into better cells. Xing et al. (Inflammation and Regeneration, 2026; PMID 42324588) report MOTS-C-treated obese-donor MSCs showed reduced proliferation, elevated p16/p21 senescence markers, and higher TNF-alpha versus untreated controls. In a mouse renal artery stenosis model, MOTS-C-pretreated MSCs failed to improve renal perfusion or fibrosis, and blunted the reparative effect of lean-donor MSCs. AMPK activation and cell-source biology are separate variables, not the same lever. This is the kind of finding serious peptide research sits with instead of flattening every AMPK result into one clean story. Explore MOTS-C research through the profile link: linktr.ee/ModernAminosOf… Use code XLCRGS for 10% off your order.

Discover BPC-157: its first randomized, placebo-controlled human trial is now recruiting. Thirty years of preclinical data and exactly one prior human study defined the evidence base until now. A 2025 systematic review in the HSS Journal (Vasireddi et al., PMID 40756949) screened 544 articles on BPC-157 and included 36: 35 preclinical studies and one clinical retrospective. A new Phase 2 trial (NCT07437547, sponsor Hudson Biotech) is testing BPC-157 against placebo in 120 participants with MRI-confirmed acute Grade II hamstring strain, randomized and double-blind. Primary completion is projected for February 2027. Track the readout as the first controlled human data on this peptide lands. Shop US, CA, EU: linktr.ee/ModernAminosOf… Use code XLCRGS for 10% off your order.

Retatrutide's weight loss response traces to a specific metabolite signature, not just appetite suppression, according to new post-hoc metabolomics data. The analysis combined two Phase 2 RCTs (282 participants with obesity; 213 with type 2 diabetes) and was published in the Journal of Clinical Endocrinology and Metabolism, 2026 (Pearson et al., Eli Lilly and Duke; PMID 42135195; DOI 10.1210/clinem/dgag201). A fatty acid oxidation and ketone biomarker cluster (3-hydroxybutyrate; acetylcarnitine; free carnitine; long-chain acylcarnitines) statistically mediated 23.2% of the weight-loss response in participants without diabetes, falling to 12.7% in participants with type 2 diabetes. A separate insulin-resistance metabolite cluster (branched-chain amino acids; urate; saturated-chain triglycerides) shifted favorably alongside it, pointing to a mechanism that runs through metabolic flexibility as well as intake. Carnitine-dependent fatty acid transport sits inside that oxidation cluster, the same pathway Modern Aminos' L-Carnitine and NAD+/Carnitine Blend research lines are built around. Use code XLCRGS for 10% off your order. modernaminos.com/product/glp-gi…

Same peptide. Same aged mice. Two delivery routes producing opposite gene expression programs in the hippocampus. A new preprint out of the University of Washington (Mazzola et al., Research Square, not yet peer reviewed) tracked GHK-Cu in 20 to 21 month old C57BL/6J mice and found the delivery route determines which biological program activates.

Unlock Hexarelin: a hexapeptide GHRP studied as a potent GHSR-1a agonist and GH secretagogue, with cardioprotective pathways explored in preclinical models. BPC-157 continues to anchor tissue repair research, investigated for angiogenesis, cytoprotection, and systemic regeneration. Both are part of the weekend buy one get one free offer, and it closes tonight at midnight ET. Add two of the same product to cart. Second one is free, applied automatically at checkout. No code needed for the BOGO. Stock is limited while supplies last. Shop US, CA, EU: linktr.ee/ModernAminosOf… Use code XLCRGS for 10% off your order. For research purposes only. Not for human consumption.

@ModernAminos not measured sir. from other patients’ data, the formulation appears to have little to no effect on systemic DHT to learn more: anagen.xyz/treatment-scie…

Two months of MINX and Precision Dutasteride MAXX. What do we think?

Retatrutide vs tirzepatide vs semaglutide vs survodutide vs mazdutide: three independent meta-analyses from 2025 and 2026 ranked these incretin agents head to head, and the rankings do not agree. One favors semaglutide and tirzepatide on outcomes, two rank retatrutide highest on weight, and a fourth isolates mazdutide for tolerability. Here is what each analysis actually found.

Route of administration shapes which pathway a peptide engages, not just how much reaches circulation, a distinction worth tracking across copper peptide research. Modern Aminos carries GHK-Cu standalone, plus Glow and KLOW formulations pairing it with TB-500, BPC-157, and KPV, for laboratory and research use only, not for human consumption. Use code XLCRGS for 10% off your order. Shop: linktr.ee/ModernAminosOf…

Intraperitoneal GHK-Cu ran a 5 day course and produced only a transient improvement, and only in males. Instead of the oxidative phosphorylation shift seen with intranasal dosing, this route activated DNA repair and stress response pathways. Both routes improved learning in aged mice. The gene programs driving that improvement were opposite.

MK-677 has a bigger Phase 2 pedigree than most people realize. Merck Sharp and Dohme sponsored a Phase 2 trial (NCT00074529, n=512) testing MK-0677, the same compound sold today as MK-677 or ibutamoren, at 25mg for slowing the progression of Alzheimer's Disease. It completed years ago and rarely comes up when the compound is discussed. That trial was not the only one. Merck also ran a Phase 2 fibromyalgia trial (NCT00116129, n=64). The University of Virginia studied MK-677's effects on body composition and functional ability in older adults in a Phase 1/2 trial (NCT00474279, n=72). Massachusetts General Hospital evaluated ibutamoren for NAFLD and NASH in a Phase 2 trial that completed in 2024 (NCT05364684, n=12). A GH secretagogue with a research trail spanning neurodegeneration, metabolic disease, and aging, not just gym shelves. See the full MK-677 research profile: modernaminos.com/product/mk-677/ Use code XLCRGS for 10% off your order.

Buy one, get one free this weekend on BPC-157 5MG and Hexarelin 10MG. BPC-157: pentadecapeptide investigated for tissue repair and angiogenesis models. Hexarelin: potent GHSR-1a agonist studied as a GH secretagogue in preclinical models. Add two of the same product to cart. The second one is free, applied automatically at checkout. No code needed for the BOGO. Valid through Sunday at midnight ET while supplies last. Shop US, CA, EU: linktr.ee/ModernAminosOf… Use code XLCRGS for 10% off your order. For research purposes only. Not for human consumption.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist studied in a new Phase 3 diabetes trial. The TRANSCEND-T2D-1 trial (Bajaj et al., Lancet, 2026) ran retatrutide as monotherapy across 48 sites over 40 weeks in 537 participants at 4, 9, and 12mg doses. At the 12mg dose, researchers reported 15.3% body weight reduction versus 2.6% for placebo, and HbA1c reduction of 1.94% versus 0.81% for placebo. Triple incretin agonism keeps producing some of the strongest metabolic signals in GLP-1 research right now. For research purposes only. Not for human consumption. Use code XLCRGS for 10% off your order. Shop: modernaminos.com/product/glp-gi…

Line the four analyses up and the disagreement resolves into a tradeoff, not a contradiction. Semaglutide and tirzepatide carry the deepest outcomes data on mortality and MACE, while retatrutide and survodutide lead on raw weight change through broader receptor engagement. Mazdutide trades some of that weight effect for the strongest tolerability profile in the group. Sources: Damen et al. Ann Intern Med 2026; Yan et al. Acta Diabetol 2025; Xie et al. Metabolism 2024; Abulehia et al. Endocrinol Diabetes Metab 2026. Modern Aminos stocks GLP/GIP/Glucagon (RT), the triple agonist studied as retatrutide, and Mazdutide 5MG for glucagon/GLP-1 dual agonism research. Shop US, CA, EU: linktr.ee/ModernAminosOf… Use code XLCRGS for 10% off your order.

Abulehia et al. (Endocrinology, Diabetes and Metabolism, 2026) ran a network meta-analysis spanning retatrutide, survodutide, mazdutide, and cotadutide. Weight reduction ranked retatrutide above survodutide above mazdutide above cotadutide, while mazdutide posted the best tolerability profile of the group. Mechanism breadth tracks with weight effect size here, but tolerability moves independently of it.